老年缺血性卒中后患者奥氮平直肠给药的临床疗效观察

摘要/Abstract

摘要：

目的探讨奥氮平直肠给药对老年缺血性卒中后患者谵妄的治疗效果及安全性。方法采用前瞻性研究的方法，将解放军总医院第一附属医院干二科2013年3月1日～2014年2月18日收治的60例缺血性卒中后谵妄的住院患者分为口服给药组及直肠给药组。两组患者均在谵妄发生后 24 h内给予奥氮平治疗。用药前及用药1周后对两组均进行谵妄评定量表（Confusion Assessment Method， CAM）及美国国立卫生研究院卒中量表（National Institutes of Health Stroke Scale，NIHSS）评分分别评估两组患者用药前及用药后的谵妄严重情况及卒中严重程度。比较两组患者用药治疗1周后的用药平均剂量、治疗效果及副作用等。3个月后对两组患者进行改良Rankin量表（modified Rankin Scale，mRS）评分随访以评估药物治疗是否影响缺血性卒中患者的预后。结果 ①口服给药和直肠给药两组患者年龄、性别、1周内NIHSS及CAM得分差异均无显著性：NIHSS中位数（8.5 vs 10；P =0.79）、CAM［（25.8±3.1）vs（26.1±5.3）；P =0.79］；两组患者合并高血压病、糖尿病、冠状动脉粥样硬化性心脏病比例差异无显著性：高血压病（6.7% vs 2.0%；P =0.18）、糖尿病（10.0% vs 23.3%；P =0.17）、冠状动脉粥样硬化性心脏病（50.0% vs 60.0%；P =0.4３）；两组患者缺血性卒中部位比较差异无显著性（P =0.76）。②口服给药和直肠给药两组均未发生明显副作用。直肠给药组1周内平均给药剂量明显低于口服给药组［（5.33±2.12）vs（4.25±2.06）；P =0.03］。③用药1周后，直肠给药组CAM、NIHSS评分均明显低于口服给药组：CAM［（19.8±3.９）vs（15.2±2.1）；P =0.00］、 NIHSS中位数（7.5 vs 6.5；P =0.00）。3个月后随访mRS得分提示两组之间差异无显著性（P =0.15）。结论老年缺血性卒中后谵妄患者，尤其是口服给药困难者，直肠给药可能是一种较安全有效的替代方式，但用药剂量尽量小于口服给药剂量。

文章导读： 初步探讨了奥氮平直肠给药的安全性及有效性，为急性缺血性卒中后谵妄患者的急性期症状控制提
供了一种有效的干预方式和给药途径。

关键词: 谵妄; 卒中; 奥氮平; 直肠给药

Abstract:

Objective To investigate the effectivity and safety about olanzapine administered rectally for ischemic stroke old patients. Methods Sixty patients (aged ≥65 years) admitted to the Department of Cardre Ward-2 of the First Affiliated Hospital of the General Hospital of People's Liberation Army (PLA) from March 2013 with delirium after a recent stroke was accepted. All these 60 patients were randomly divided into two groups to accept with olanzapine orally or rectally, respectively. All the patients fulfilled the National Institutes of Health Stroke Scale (NIHSS) and the Confusion Assessment Method (CAM) scale before and one week after they used the drug of olanzapine. Compare the baseline data, severity of the stroke and the delirium. One week after the patients used the drug, compare the mean dose of olanzapine, the treatment effect and the side effect of the two groups. We followed up all the 60 patients with modified Rankin Scale (mRS) after 3 months to evaluate the prognosis of the two methods of administration. Results ①There is no significant difference between the oral group and the rectal group on the age, gender and the score of NIHSS and CAM: Media of NIHSS (8.5 vs 10; P =0.79)、CAM ([25.8±3.1] vs [26.1±5.3]; P =0.79). Also the comorbidity of hypertension (6.7% vs 2.0%; P =0.18), diabetes (10.0% vs 23.3%; P =0.17) and coronary heart disease (CHD) (50.0% vs 60.0%; P =0.43) have no significant differences between the two groups. ②Both two groups' olanzapine orally and rectally are both well tolerated among these patients, and there is no significant side effect on those 60 patients in the first week ([5.33±2.12] vs [4.25±2.06]; P =0.03). ③The follow-up data after 3 months showed that there was no significant difference between the two groups in the score of mRS (P =0.15). Conclusion Olanzapine administered rectally may be an effective and safe method for delirium patients, especially for those patients who are difficulty in taking oral medicine. And the dose of rectal use should be less than that of oral use.

Key words: Delirium; Stroke; Olanzapine; Rectal administration

傅小玲1，石玉芝2，高畅1，楚勤英1，李建华1，舒刚明1. 老年缺血性卒中后患者奥氮平直肠给药的临床疗效观察[J]. 中国卒中杂志, 2014, 9(12): 1007-1012.

FU Xiao-Ling, SHI Yu-Zhi, GAO Chang, CHU Qing-Ying, LI Jian-Hua, SHU Gang-Ming.. Study on the Treatment Effectiveness of Per Rectum Olanzapine for Patients with Delirium Post-Stroke[J]. Chinese Journal of Stroke, 2014, 9(12): 1007-1012.

参考文献

1 Kutlubaev MA, Akhmadeeva LR, Bikbulatova LF.

Delirium in the acute phase of stroke:frequency and

predisposing factors[J]. Zh Nevrol Psikhiatr Im S S

Korsakova, 2013, 113:37-41.

2 Kennedy M, Enander RA, Tadiri SP, et al. Delirium

risk prediction, healthcare use and mortality of elderly

adults in the emergency department[J]. J Am Geriatr

Soc, 2014, 623:462-469.

3 Young J, Inouye SK. Delirium in older people[J]. BMJ,

2007, 334:842-846.

4 孙新宇. 卒中后神经精神障碍一例[J]. 中国卒中杂志,

2008, 3:686-689.

5 Wa n g H R , Wo o YS , Ba h k WM. At y p i c a l

antipsychotics in the t reatment of delirium[J].

Psychiatry Clin Neurosci, 2013, 67:323-331.

6 Rooney S, Qadir M, Adamis D, et al. Diagnostic and

treatment practices of delirium in a general hospital[J].

Aging Clin Exp Res, 2014, 26:625-633.

7 San L, Casillas M, Ciudad A, et al. Olanzapine

orally disintegrating tablet:a review of efficacy and

compliance[J]. CNS Neurosci Ther, 2008, 143:203-

214.

8 王明丽, 蒋军, 王莉英. 直肠给药新制剂的研究进展

[J]. 药学与临床研究, 2007, 15:344-346.

9 No authors listed. The World Health Organization

MONICA Project (monitoring trends and determinants

in cardiovascular disease):a major international

collaboration. WHO MONICA Project Principal

Investigators[J]. J Clin Epidemiol, 1988, 412:105-114.

10 Schmidt R, Petrovic K, Ropele S, et al. Progression

of leukoaraiosis and cognition[J]. Stroke, 2007,

389:2619-2625.

11 魏娜, 沈东超, 张玉梅, 等. 缺血性卒中合并脑白质病

变的危险因素研究[J]. 中国卒中杂志, 2011, 6:960-

966.

12 Carin-Levy G, Mead GE, Nicol K, et al. Delirium

in acute stroke:screening tools, incidence rates and

predictors:a systematic review[J]. J Neurol, 2012,

259:1590-1599.

13 李娟, 邹义壮, 冯峰, 等. 谵妄评定方法修订及其信度

效度测试[J]. 临床精神医学杂志, 2003, 13:147-149.

14 Shi Q, Warren L, Saposnik G, et al. Confusion

assessment method:a systematic review and metaanalysis

of diagnostic accuracy[J]. Neuropsychiatr

Dis Treat, 2013, 9:1359-1370.

15 Mc Manus J, Pathansali R, Hassan H, et al. The

evaluation of delirium post-stroke[J]. Int J Geriatr

Psychiatry, 2009, 24:1251-1256.

16 van Swieten JC, Koudstaal PJ, Visser MC, et al.

Interobserver agreement for the assessment of

handicap in stroke patients[J]. Stroke, 1988, 19:604-

607.

17 周立峰, 章磊, 冯炯. 54例急性脑卒中后谵妄的相关因

素分析[J]. 中国临床神经科学, 2009, 17:71.

18 Hüfner K, Sperner-Unterweger B. Delirium in patients

with neurological diseases:Diagnosis, management

and prognosis[J]. Nervenarzt, 2014, 85:427-436.

19 McManus J, Pathansali R, Stewart R, et al. Delirium

post-stroke[J]. Age Ageing, 2007, 36:613-618.

20 Oldenbeuving AW, de Kort PL, van Eck van der Sluijs

JF, et al. An early prediction of delirium in the acute

phase after stroke[J]. J Neurol Neurosurg Psychiatry,2014, 85:431-434.

21 Neerland BE, Watne LO, Wyller TB. Delirium in

elderly patients[J]. Tidsskr Nor Laegeforen, 2013,

133:1596-1600.

22 杨进玉. 急性卒中后谵妄的临床特点[J]. 临床神经病

学杂志, 2012, 25:253, 277.

23 Chemer inski E, Levine SR. Neuropsychiat r ic

disorders following vascular brain injury[J]. Mt Sinai

J Med, 2006, 73:1006-1014.

24 Yoon HJ, Park KM, Choi WJ, et al. Efficacy and

safety of haloperidol versus atypical antipsychotic

medications in the treatment of delirium[J]. BMC

Psychiatry, 2013, 13:240.

25 Kinon BJ, Hill AL, Liu H, et al. Olanzapine orally

disintegrating tablets in the treatment of acutely ill

non-compliant patients with schizophrenia[J]. Int J

Neuropsychopharmacol, 2003, 62:97-102.

26 McDonnell DP, Landry J, Detke HC. Long-term

safety and efficacy of olanzapine long-acting injection

in patients with schizophrenia or schizoaffective

disorder:a 6-year, multinational, single-arm, openlabel

study[J]. Int Clin Psychopharmacol, 2014,

29:322-331.

27 夏俊华. 药物的剂型对吸收的影响[J]. 河北医学, 2007,

13:1382-1383.

28 Turco R, Bellelli G, Morandi A, et al. The effect

of poststroke delirium on short-term outcomes of

elderly patients undergoing rehabilitation[J]. J Geriatr

Psychiatry Neurol, 2013, 262:63-68.

29 Sheng AZ, Shen Q, Cordato D, et al. Delirium within

three days of stroke in a cohort of elderly patients[J]. J

Am Geriatr Soc, 2006, 54:1192-1198.

[1]	鲁燕, 杨保荣, 黄向萍, 杨冠桂, 陈圣文, 李建荣, 曾小明. 县级医院急性缺血性卒中超时间窗经MRI筛选溶栓的病例对照研究 [J]. 中国卒中杂志, 2022, 17(12): 1321-1326.
[2]	楚悦琪, 周凯云, 王田燕, 王炯彬, 李真. 卒中后吞咽障碍应用耳穴压豆治疗效果的meta分析 [J]. 中国卒中杂志, 2022, 17(12): 1327-1334.
[3]	周甜甜, 苏文杰, 连松勇, 林友聪. 丰富环境对卒中后血管性痴呆患者认知功能的影响 [J]. 中国卒中杂志, 2022, 17(12): 1343-1349.
[4]	吴娱倩, 张玉梅, 范小伟, 王安心, 逄文斌. 运动想象-动觉治疗对缺血性卒中患者手功能康复效果的研究[J]. 中国卒中杂志, 2022, 17(12): 1366-1371.
[5]	蒋林, 李靖. 基于知识图谱分析人工智能用于卒中研究的现状及趋势 [J]. 中国卒中杂志, 2022, 17(12): 1372-1380.
[6]	梁潇, 钱海兵. 水通道蛋白4与卒中后认知障碍的关系研究进展[J]. 中国卒中杂志, 2022, 17(12): 1385-1390.
[7]	吴晓莉, 刘丽旭. 肥胖对卒中预后的影响[J]. 中国卒中杂志, 2022, 17(12): 1391-1395.
[8]	伊珞, 周宏宇, 仇鑫, 李子孝, 王拥军. 动脉粥样硬化性疾病的DNA甲基化改变[J]. 中国卒中杂志, 2022, 17(11): 1163-1170.
[9]	王誉博, 李子孝, 王拥军. 表观遗传学与缺血性卒中后氧化应激的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1171-1177.
[10]	闫然, 闵妍, 全柯华, 李子孝. 脑源性神经营养因子和血清素再摄取转运体编码基因甲基化与卒中预后的关系[J]. 中国卒中杂志, 2022, 17(11): 1178-1182.
[11]	崔凌云, 仇鑫, 周宏宇, 李子孝, 王拥军. DNA甲基化与2型糖尿病的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1183-1188.
[12]	邓宇含, 刘爽, 王子尧, 汪雨欣, 刘宝花. 基于结构化数据和机器学习模型预测普通人群卒中发病风险的系统评价和meta分析 [J]. 中国卒中杂志, 2022, 17(11): 1189-1197.
[13]	刘光亮, 韩凯月, 苏文龙, 张皓. 不同强度有氧踏车训练对不同病程缺血性卒中患者运动和心肺适能的影响 [J]. 中国卒中杂志, 2022, 17(11): 1203-1208.
[14]	孙默一, 张玉梅, 刘然, 赵依双. 不同时间康复介入对卒中患者运动功能的影响 [J]. 中国卒中杂志, 2022, 17(11): 1209-1215.
[15]	胡红梅, 杨磊, 于玲, 秦伟, 白明悦, 胡文立. 急性单发小脑小梗死的临床特征 [J]. 中国卒中杂志, 2022, 17(11): 1221-1226.